Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:CORT
CUSIP21835210
Phone650-327-3270
Debt
Debt-to-Equity RatioN/A
Current Ratio6.39
Quick Ratio6.23
Price-To-Earnings
Trailing P/E Ratio32.61
Forward P/E Ratio23.92
P/E GrowthN/A
Sales & Book Value
Annual Sales$159.20 million
Price / Sales10.46
Cash Flow$0.45 per share
Price / Cash31.89
Book Value$1.67 per share
Price / Book8.59
Profitability
EPS (Most Recent Fiscal Year)$0.44
Net Income$129.12 million
Net Margins68.32%
Return on Equity38.53%
Return on Assets33.42%
Miscellaneous
Employees136
Outstanding Shares116,050,000
Market Cap$1.70 billion
Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions
What is Corcept Therapeutics' stock symbol?
Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."
How were Corcept Therapeutics' earnings last quarter?
Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.24 by $0.04. The biotechnology company had revenue of $62.31 million for the quarter, compared to the consensus estimate of $68.49 million. Corcept Therapeutics had a net margin of 68.32% and a return on equity of 38.53%. The company's revenue was up 75.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.13 EPS. View Corcept Therapeutics' Earnings History.
When is Corcept Therapeutics' next earnings date?
What price target have analysts set for CORT?
5 brokerages have issued 12-month price targets for Corcept Therapeutics' stock. Their forecasts range from $11.00 to $32.00. On average, they anticipate Corcept Therapeutics' stock price to reach $22.40 in the next year. This suggests a possible upside of 56.1% from the stock's current price. View Analyst Price Targets for Corcept Therapeutics.
What is the consensus analysts' recommendation for Corcept Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corcept Therapeutics.
Are investors shorting Corcept Therapeutics?
Corcept Therapeutics saw a decrease in short interest during the month of August. As of August 15th, there was short interest totalling 15,148,191 shares, a decrease of 16.4% from the July 31st total of 18,122,510 shares. Based on an average daily trading volume, of 1,915,894 shares, the short-interest ratio is currently 7.9 days. Approximately 14.8% of the company's shares are sold short. View Corcept Therapeutics' Current Options Chain.
Who are some of Corcept Therapeutics' key competitors?
Some companies that are related to Corcept Therapeutics include Alkermes (ALKS), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GW Pharmaceuticals PLC- (GWPH), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Endo International (ENDP) and Intercept Pharmaceuticals (ICPT).
Who are Corcept Therapeutics' key executives?
Corcept Therapeutics' management team includes the folowing people:
- Dr. Joseph K. Belanoff, Co-Founder, CEO, Pres & Director (Age 61)
- Mr. Gary Charles Robb, CFO, Chief Accounting Officer & Sec. (Age 55)
- Mr. Sean Maduck, Sr. VP of Commercial (Age 41)
- Dr. Robert S. Fishman, Chief Medical Officer (Age 56)
- Dr. Hazel Hunt Ph.D., Sr. VP of Research
Who are Corcept Therapeutics' major shareholders?
Corcept Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.32%), Federated Investors Inc. PA (10.34%), Ingalls & Snyder LLC (6.35%), Renaissance Technologies LLC (3.77%), Acadian Asset Management LLC (2.42%) and Dimensional Fund Advisors LP (1.44%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright, Renee D Gala and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.
Which major investors are selling Corcept Therapeutics stock?
CORT stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Nexthera Capital LP, Acadian Asset Management LLC, Renaissance Technologies LLC, Russell Investments Group Ltd., American Century Companies Inc., Globeflex Capital L P and GSA Capital Partners LLP. Company insiders that have sold Corcept Therapeutics company stock in the last year include G Leonard Baker Jr and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.
Which major investors are buying Corcept Therapeutics stock?
CORT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Ingalls & Snyder LLC, Fuller & Thaler Asset Management Inc., KBC Group NV, AJ Wealth Strategies LLC, HL Financial Services LLC, Wells Fargo & Company MN and Oak Ridge Investments LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr, Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.
How do I buy shares of Corcept Therapeutics?
Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corcept Therapeutics' stock price today?
One share of CORT stock can currently be purchased for approximately $14.35.
How big of a company is Corcept Therapeutics?
Corcept Therapeutics has a market capitalization of $1.70 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.
What is Corcept Therapeutics' official website?
How can I contact Corcept Therapeutics?
Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]
MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
